FT News Briefing Treatments for Alzheimer’s, finally
Jul 21, 2023
The Nasdaq Composite faced a sharp decline, driven by disappointing earnings from major tech companies. In Thailand, the election winner's parliamentary suspension raises questions about democracy and stability. Meanwhile, exciting breakthroughs in Alzheimer’s treatment are highlighted, with new drugs showing promise in slowing disease progression. The podcast also discusses advancements in diagnostic tools and innovative blood tests for early detection, emphasizing the importance of ongoing research in the fight against Alzheimer’s.
AI Snips
Chapters
Transcript
Episode notes
NASDAQ Decline
- The NASDAQ composite experienced its largest single-day decline since March, exceeding 2%, influenced by disappointing earnings from Netflix and Tesla.
- This raises concerns about the potential end of the tech sector's recent rally, especially given the reliance on AI-focused companies.
Thai Election Winner Suspended
- Pita Limjaroenrat, leader of Thailand's Move Forward Party, was suspended from parliament due to a technicality involving shares in a defunct TV station.
- This move reflects the establishment's resistance to the party's reformist agenda, posing a threat to their power.
Alzheimer's Breakthroughs
- Two new Alzheimer's drugs, donanemab and lecanemab, offer significant advancements in treatment by slowing disease progression.
- These drugs target amyloid protein buildup in the brain, marking a major breakthrough in Alzheimer's research.